Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Investor Presentation (April 2019)
25 slides from Sanuwave Health's investor presentation, Apr 2, 2019
Slide 1: Healing today. Curing tomorrow.
SANLUVVAVE Healing today. Curing tomorrow. Creating a brighter future by providing novel and cost effective solutions, focused on societal needs with the sole purpose of bettering lives everywhere OTCQB: April 2019
Slide 2: Forward-Looking Statement Disclaimer
Forward-Looking Statement Disclaimer This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective.
Slide 3: SANUWAVE Health
SANUWAVE Health SANUWAVE Health (SNWV), Inc. is an emerging shockwave technology company focused on the development and commercialization of patented noninvasive, high-energy, acoustic focused, shockwaves for the repair and regeneration of tissue, musculoskeletal and vascular structures. FDA permitt
Slide 4: Investment Highlights & Recent Developments
Investment Highlights & Recent Developments Accomplishments in 2018 Goals for 2019 Hired Shri Parikh, President Healthcare * 100 US Placements ; 300 certified users Received reimbursement tracking for DFU procedure * Reimbursement; finish with at least 10 million Signed Premier Shockwave as the excl
Slide 5: A Leader in Shockwave Technology
A Leader in Shockwave Technology Development and Commercialization Patented, non-invasive devices for the repair and regeneration of: * Skin * Musculoskeletal tissue + Vascular structures Devices activate biologic signaling and angiogenic responses, producing: * New vascularization Immediate microci
Slide 6: Global Wound Care Market Overview
Global Wound Care Market Overview Medical burden of wounds drives new technology investments US and worldwide wound prevalence ‘Types of wound US prevalence Worldwide Healing time: Estimated CAGR (=) _ prevalence (m) (days) (200766) ‘Surgical wounds 7 1103 “ 36% ‘Traumate wounds NA 16 2a 17% Lacerat
Slide 7: U.S. Wound Care Market Overview
U.S. Wound Care Market Overview Prevalence of wounds US prevalence of all wounds USS. prevalence of hard-to-heal wounds* (8 million pa) (3.2 million pa) Diabete fot Veneus cer cer 15% ra Adel cer “ j ~~ Trouma! ‘surgeal 13% iz Pressure u Burns ‘u% Source: BioMe
Slide 8: The dermaPACE System meets the market need for better outcomes at lower cost
The dermaPACE® System meets the market need a for better outcomes at lower cost Key Industry Needs 696808 oO BROADER ACCESS REDUCED COSTS IMPROVED HEALTH BETTER PATIENT TO CARE OUTCOMES CARE EXPERIENCE
Slide 9: The dermaPACE System positions SANUWAVE for large revenue potential
tit The dermaPACE® System positions SANUWAVE for large [ieee revenue potential Billion cost crn across wound indications in the United States costs. All c pay
Slide 10: The dermaPACE System positions SANUWAVE for success in large and emerging markets
The denmaPite® i i— System + Aging population * Clinical Reach ale * Chronic illnesses practice/education * Funding positions * Emerging middle * Innovation = Regulatory SANUWAVE class environment or contin. TT SS success in 5 More than 130m wounds “ Soares largeand =» 500 emerging 10 | 250 k 0 Eisa
Slide 11: Strategy to Capture Growth Opportunities
Strategy to Capture Growth Opportunities U.S. launch of dermaPACE Sales coverage ramp up "Enhanced commercialization Broader Access Drive Global Expansion infrastructure = Emerging markets Reduce Cost & imerove Deliver Economic Value «Value-added solutions Efficiency 7 and services that offer clinic
Slide 12: Market Opportunity with The dermaPACE System
Market Opportunity with The dermaPACE® System U.S Market Diabetic Foot Ulcers - $4B+ market size. 29 million people living with diabetes and 86 million pre-diabetics. 25% of diabetics will acquire a non-healing ulcer in their lifetime; ~3 million diabetic ulcers annually. Diabetic foot ulcers lead t
Slide 13: The dermaPACE System Treating Diabetic Foot Ulcers
The dermaPACE® System a” Treating Diabetic Foot Ulcers iS ® Ed a E Robust closure with Non-invasive, convenient, Mechanism of action Cost-effective May be used as an adjunct. extremely low recurrence and safe (MOA) allows : therapy rates S-
Slide 14: U.S. Market Strategy
>10 million Pressure Sores 45 Million alu 10 Millio® vw 33 Million 19 Miilion oFU U.S. Market Strategy increase in usage WWW 100 1600 2,200 2022 Wound Goal Care Centers 10,000 Hospital Outpatient, in Office and Assisted Living Care
Slide 15: Growth Strategy
Growth Strategy Seek relationships with qualified partners and JV/licensing agreements * Address advanced wound care market - large and growing Y Domestic rollout of 2,000 placements; 500,000 treatments (with increasing indication) and greater than $100 million in revenue in 5 years v International
Slide 16: Business Model Transformation
Business Model Transformation Transform from a product company to a provider of comprehensive value propositions and solutions that address the wound care patient pathway
Slide 17: Clinical studies timeline
Loe Action Pharmacoeconomic DFU2 New AWC VLU Pressure Ulcer ALU Mechanism of Action Vascularization/Perfusion/Dosing Surgical Incisions/Cosmetic Dr. Siemionow Domestic/US Global Domestic/US Global Clinical Studies Sites 12+ w Qi Q2 Q3 Q4 Qi Q2 Q3 a4
Slide 18: Intellectual Property (IP) Organic Growth
Intellectual Property (IP) Organic Growth | 2006 7012 | 2018 S Patents 14 18 [Foreign Patents 10 9 [US Appl(s) 11 9 Foreign Applls) 2 10 ; HroTAL 37 46 @ bercentage 2a Orthopedis, 7 Arthas, Ischemia, | Ischemia, Spinal a, Spinal Boos en Device Design Sterilization, Device Design
Slide 19: Device Sales — Historical and 2019 Projection
eo evice Sales — Historical and 2019 Projection = 140 120 120 4 S 2016 2018 2019 projection 16 . 9 10 ‘oe 205 2012 2013
Slide 20: Non-Medical Markets
Non-Medical Markets Addressable opportunities covered by Patents Energy Production Water = Advanced Fracking = Fracking Water Cleaning = Improved / Enhanced Oil = Industrial Water Cleaning Extraction Recovery = Drinking Water Cleaning Food Industry Industrial Biofilms = Preservation = Biofilm Destru
Slide 21: Wound Care Industry Valuations and Comparison
Wound Care NASDAQ: SOLY $100M + Company Name Ticker Symbol Market Cap (as of 3/28/19) Indu stry Integra Life Sciences Holding Corp. NASDAQ: IART $4.78 —_ Va | uations Convatec Group Ple LSE: CTEC $2.88 Vericel Corporation NASDAQ; VCEL $763M and s °1 i NASDAQ: ORGO 736M Comparison — osreseres ° a Osi
Slide 22: Select Financial Information
Select Financial Information | )\(2), Due to HealthTronics, Inc. as part of original 2005 purchase price | SANUWAVE
Slide 23: Management Team
Management Team Kevin Richardson II, CEO and Chairman of the Board — Joined August 2005 e Joined the Company as chairman of the board of directors in August of 2005. Brings a broad array of financial knowledge for healthcare information technology)ifinanelal services, business services and other ind
Slide 24: Why Invest in SANUWAVE
Why Invest in SANUWAVE - The dermaPACE® System received FDA Clearance on 12/28/2017 - SANUWAVE contracted with Premier Shockwave in the US as the distributor for the Veteran's Association and the Indian Health Reservation - Internationally signed 15 new countries in 2018 - Equipment Finance agreemen
Slide 25: SANUWAVE Health, Inc. contact
SANLVVAVE' Healing today. Curing tomorrow. To be viewed by the world as a diverse compassionate global family that provides positive impact on life and environment, one shock at a time. OTCQB: SNWV SANUWAVE Health, Inc. 3360 Martin Farm Road, Suite 100 Suwanee, GA 30024 info@sanuwave.com +1(770) 419